US · APRE
Aprea Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02116
- Website
- atrinpharma.com
Price · as of 2024-12-31
$0.82
Market cap 6.41M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.65 | +4,258.19% |
| Intrinsic Value(DCF) | $1.59 | +94.38% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $726.80 | ||||
| 2020 | $119.20 | ||||
| 2021 | $34.60 | ||||
| 2022 | $5.04 | ||||
| 2023 | $7.13 | ||||
| 2024 | $2.33 | $35.65 | $1.62 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Aprea Therapeutics, Inc.'s (APRE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.65
- Current price
- $0.82
- AI upside
- +4,258.19%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.59
+94.38% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| APRE | Aprea Therapeutics, Inc. | $0.82 | 6.41M | +4,258% | +94% | — | — | -0.99 | 0.66 | 8.54 | 0.70 | — | 0.66 | -523.16% | -953.00% | -862.43% | -68.98% | 415.99% | -55.58% | 0.00 | — | 7.01 | 6.80 | 1.60 | -4051.00% | 15763.00% | 1061.00% | -105.72% | -4.03 | 394.27% | 0.00% | 0.00% | 9.68% | 0.70 | 0.74 | -6.66 | -17.99 |
| ACXP | Acurx Pharmaceuticals, In… | $1.50 | 2.38M | — | — | — | — | -0.55 | 12.65 | — | — | — | 12.65 | 0.00% | — | — | -534.03% | 478.14% | -243.85% | 0.00 | — | 1.19 | 1.16 | — | -2355.00% | — | 594.00% | -133.41% | -3.20 | 352.03% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -34.86 |
| ADIL | Adial Pharmaceuticals, In… | $2.53 | 2.43M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| APVO | Aptevo Therapeutics Inc. | $7.32 | 6.85M | — | — | — | — | -0.03 | 0.15 | — | 0.14 | — | 0.15 | 0.00% | — | — | -284.28% | -3555.20% | -119.36% | 0.97 | — | 1.72 | 1.40 | 0.17 | -9623.00% | — | 10277.00% | -3391.13% | -3.83 | -3437.14% | 0.00% | 0.00% | 0.00% | 0.14 | 0.14 | — | -27.06 |
| BCDA | BioCardia, Inc. | $1.29 | 7.48M | +6,369% | -19% | — | +16,927% | -0.90 | 8.59 | 123.95 | -0.73 | — | 8.59 | -7463.79% | -13794.83% | -13700.00% | 2074.67% | 810.64% | -236.81% | 1.14 | — | 1.13 | 1.02 | 0.18 | -6459.00% | -8784.00% | -1957.00% | -111.72% | -3.46 | 813.78% | 0.00% | 0.00% | 22.70% | -0.72 | -0.72 | 99.47 | -65.68 |
| CELZ | Creative Medical Technolo… | $1.81 | 4.67M | +18,729% | +39% | — | — | -1.12 | 0.97 | 558.52 | -0.04 | — | 1.06 | 60.00% | -52216.92% | -49940.74% | -65.85% | -1515.86% | -63.20% | 0.00 | — | 18.73 | 18.13 | 1.05 | -133.00% | 2222.00% | -3478.00% | -86.29% | -16.18 | -1399.06% | 0.00% | 0.00% | 43.11% | -0.04 | -0.04 | 18.49 | -4.10 |
| GLTO | Galecto, Inc. | $29.58 | 47.25M | — | — | — | — | -0.22 | 0.30 | — | 0.45 | — | 0.30 | 0.00% | — | — | -89.03% | -3844.56% | -77.45% | 0.00 | — | 14.07 | 12.58 | 0.67 | -4864.00% | — | -4955.00% | -396.40% | -15.56 | -3216.41% | 0.00% | 0.00% | 0.00% | 0.42 | 0.50 | — | -23.70 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| INAB | IN8bio, Inc. | $1.70 | 7.88M | — | — | — | — | -13.04 | 27.41 | — | -14.50 | — | 27.41 | 0.00% | — | — | -154.44% | -359.44% | -111.38% | 0.35 | — | 4.08 | 3.61 | 0.23 | -4300.00% | — | 131.00% | -6.11% | -7.83 | -286.41% | 0.00% | 0.00% | 0.00% | -12.84 | -16.11 | — | 24.43 |
| KPRX | Kiora Pharmaceuticals, In… | $2.09 | 7.69M | — | +228% | +440% | — | 3.50 | 0.49 | 0.79 | -2.48 | — | 0.49 | 100.00% | 28.19% | 22.47% | 22.56% | 205.59% | 14.32% | 0.00 | 210.31 | 4.94 | 4.56 | -0.66 | -10359.00% | — | -18949.00% | 67.95% | 1.42 | 613.83% | 0.00% | 0.00% | 11.02% | -3.14 | -1.65 | -0.88 | -3.17 |
| RNAZ | TransCode Therapeutics, I… | $9.61 | 8.81M | — | — | — | — | -0.93 | -7.75 | — | -0.61 | — | -7.75 | 0.00% | — | — | 8866.96% | 369.89% | -268.85% | -0.02 | -584.07 | 2.56 | 2.10 | 0.36 | -9864.00% | — | -2624.00% | -85.33% | -4.81 | 315.50% | 0.00% | 0.00% | 22.07% | -0.63 | -0.74 | — | -17.50 |
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
- CEO
- Oren Gilad
- Employees
- 8
- Beta
- 1.61
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.59 ÷ $0.82) − 1 = +94.38% (DCF, example).